Assertio Therapeutics (ASRT): a supplier and advisory map for investors

Assertio is a small commercial pharmaceutical company that monetizes by selling specialty and hospital medicines, acquiring branded products, and managing royalty/licensing obligations. The company outsources virtually all manufacturing and relies on a mix of long‑term supply contracts, minimum purchase obligations, and acquired product revenue streams to drive cash flow; revenue TTM was $137.4M while market capitalization is roughly $75.5M. For investors, the core thesis is straightforward: Assertio’s revenue is operationally levered to third‑party manufacturers and a handful of commercial relationships — that concentration creates both margin upside from fixed pricing and downside risk from supplier shortages or price shocks. Learn more about the supplier relationships and implications at https://nullexposure.com/.

Why the supplier map matters for valuation and operational risk

Assertio does not operate its own manufacturing; it depends on contract manufacturers and single‑source API providers, a posture that keeps capital expenditure low but leaves the company exposed to supply and pricing risk. Public filings and disclosures show a mix of long‑term contracts (some with minimum purchase commitments), licensing royalty obligations, and geographically diversified contract manufacturing sites in the U.S., Canada, Italy and South Korea. These characteristics drive several investment constraints:

Concentration and criticality: The company states it has one qualified API supplier per product and single‑source manufacturers, creating a high operational dependency that can quickly impact sales and margins if inventories are depleted.
Contract maturity and spend profile: Assertio has long‑term supply commitments and multi‑year purchasing obligations (spend bands consistent with $1M–$100M levels), which stabilize supply but lock in cost and volume exposures.
Licensing and contingent royalties: Licensing obligations (notably for INDOCIN) establish contingent cash outflows tied to product sales thresholds through 2029.
Commercial outsourcing as strategic choice: Outsourcing lowers fixed costs and manufacturing capex but increases supplier negotiation and quality governance as key value levers.

If you want a consolidated view of Assertio’s partner network for diligence, visit https://nullexposure.com/ for the full map.

What Assertio’s named partners do for the company

Cosette Pharmaceuticals, Inc.

Assertio’s FY2024 10‑K states that the API for the INDOCIN suppository formulation is procured from Cosette Pharmaceuticals, Inc., indicating Cosette is a direct API supplier for an approved product. (Assertio 10‑K, FY2024)

Continental Stock Transfer & Trust

Continental has been appointed by Assertio to act as exchange agent for reverse stock splits announced in prior years, reflecting a role in shareholder record administration around corporate actions. (Company press release, 2021; follow‑up notices, FY2025)

The Nasdaq Stock Market LLC

Assertio’s common stock trades on Nasdaq under the ticker ASRT; recent filings and press releases confirm continued listing and trading venue. (Company press materials, FY2021–FY2025)

Spectrum Pharmaceuticals

Assertio acquired a drug in a transaction tied to Spectrum Pharmaceuticals’ portfolio, and subsequent reporting tied acquired product economics and activist dialogue to that acquisition. (FiercePharma reporting, FY2024)

Antares Pharma, Inc.

Assertio acquired Otrexup (a methotrexate auto‑injector) from Antares in a transaction disclosed in 2021, and the Antares Supply Agreement includes annual minimum purchase obligations (~$2.0M annually) with an initial term through December 2031. (Assertio/Antares press releases, 2021; company filing disclosures)

Hanmi (HAFC)

Assertio executed a long‑term supply agreement with Hanmi for the API used in Rolvedon, positioning the company for stable supply and pricing; the company disclosed significant purchases from Hanmi (about $21.1M in inventory during 2024). (Q3 2025 earnings call transcript; company filings, 2024–2025)

Stifel

Stifel acted as exclusive financial advisor to Assertio on a strategic merger transaction (Assertio–Zyla), serving in an investment banking advisory capacity. (Press release, FY2020)

H.C. Wainwright & Co.

H.C. Wainwright served as a financial advisor to Assertio in the Spectrum Pharmaceuticals acquisition process, indicating investment‑banking support for M&A activity. (Deal coverage, FY2023)

Latham & Watkins LLP

Latham & Watkins served as Assertio’s legal counsel on the Spectrum acquisition, with a published advisory note on the representation for the FY2023 transaction. (Latham & Watkins client announcement, FY2023)

SVB Securities

SVB Securities acted as a financial advisor to Assertio in the acquisition of Spectrum Pharmaceuticals, signaling senior advisory involvement in deal execution. (Deal reporting, FY2023)

Aquestive (AQST)

Industry reporting notes that Aquestive transferred a film formulation seizure drug to Assertio as part of related portfolio adjustments following the Spectrum deal. (FiercePharma reporting, FY2023)

Gibson, Dunn & Crutcher LLP

Gibson Dunn served as legal counsel to Assertio on its merger with Zyla Life Sciences, highlighting outside counsel support on corporate transactions. (Company merger announcement, FY2020)

Darrow Associates

Darrow Associates is listed as Assertio’s investor relations contact in transaction announcements, performing IR communications and investor outreach. (Deal notices and IR contact listings, FY2023)

Longacre Square Partners

Longacre Square Partners is named as an investor contact for Assertio in press materials tied to corporate actions, indicating an external IR firm role. (Press notices, FY2025)

How these relationships translate to investment risk and opportunity

Assertio’s commercial model leverages outsourced manufacturing and targeted acquisitions to grow revenue without heavy manufacturing capex. That structure creates two clear investment vectors:

Opportunity: Fixed or long‑dated supply contracts and minimum purchase obligations provide predictable supply and gross margin stability when pricing is locked and inventories are managed.
Risk: Single‑source APIs and single manufacturers for key products are a systemic operational risk; a supplier price increase or capacity failure can compress margins quickly and reduce revenue if inventory levels are exhausted.

Key takeaways for investors: monitor inventory levels, supplier contract expirations and minimums (notably Hanmi and Antares), royalty obligations (INDOCIN), and any press around supply disruptions. These items are the principal drivers of short‑term earnings volatility for a company of Assertio’s size.

For a deeper supplier and risk model tailored to portfolio diligence, explore our coverage at https://nullexposure.com/.

Final read: what to watch next

Track near‑term catalysts that change the supplier risk profile — renewals of supply agreements, material manufacturing incidents, or litigation around licensing/royalty payments — as these will directly affect cash flows. Assertio trades as a focused, outsourced commercial pharma: low capex, high supplier dependency, and concentrated event risk. If you want a mapped diligence report or an inquiry about any supplier relationship, visit https://nullexposure.com/ for direct access to our supplier intelligence and analyst briefings.

ASRT supplier relationships